Healthcare costs among patients with hematologic malignancies receiving allogeneic transplants: a US payer perspective

Richard T Maziarz,Usama Gergis,Marie Louise Edwards,Yan Song,Qing Liu, Annika Anderson, James Signorovitch,Rocio Manghani,Ronit Simantov, Heayoung Shin,Smitha Sivaraman

Blood Advances（2023）

引用 0|浏览5

暂无评分

摘要

•Due to acute and chronic care needs, allogeneic hematopoietic cell transplant (allo-HCT) is costly•Novel therapies that reduce both length of hospitalization post-HCT and complication rates may significantly reduce allo-HCT costs

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要